Impact, mechanisms, and novel chemotherapy strategies for overcoming resistance to anthracyclines and taxanes in metastatic breast cancer

@article{Perez2008ImpactMA,
  title={Impact, mechanisms, and novel chemotherapy strategies for overcoming resistance to anthracyclines and taxanes in metastatic breast cancer},
  author={E. Perez},
  journal={Breast Cancer Research and Treatment},
  year={2008},
  volume={114},
  pages={195-201}
}
  • E. Perez
  • Published 2008
  • Medicine
  • Breast Cancer Research and Treatment
Despite advances in treatment of patients with metastatic breast cancer (MBC), prognosis remains poor and median survival is 2–3 years. Resistance to antineoplastics mediated by many factors, potentially including overexpression of drug efflux proteins or altered β-tubulin isotype expression limits the effectiveness of MBC chemotherapy. Capecitabine, approved for anthracycline- and taxane-resistant MBC, has produced modest responses, highlighting the need for more effective treatments for MBC… Expand

Paper Mentions

Interventional Clinical Trial
In the second-line treatment setting for MBC, many agents, including antitubulin drugs (Taxanes, Vinorelbine) and antimetabolites (Capecitabine, Gemcitabine), have demonstrated… Expand
ConditionsHuman Epidermal Growth Factor 2 Negative Carcinoma of Breast, Metastatic Breast Cancer
InterventionDrug
Drug Resistance and the Role of Combination Chemotherapy in Improving Patient Outcomes
  • D. Yardley
  • Medicine
  • International journal of breast cancer
  • 2013
Etirinotecan pegol for the treatment of breast cancer
Chemotherapy Options beyond the First Line in HER-Negative Metastatic Breast Cancer
Multidrug Resistance in Breast Cancer: From In Vitro Models to Clinical Studies
Targeted multidrug delivery system to overcome chemoresistance in breast cancer
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 72 REFERENCES
Overcoming multidrug resistance in cancer: an update on the clinical strategy of inhibiting p-glycoprotein.
Mechanisms of cancer drug resistance.
Ixabepilone plus capecitabine for metastatic breast cancer progressing after anthracycline and taxane treatment.
  • E. Thomas, H. Gómez, +14 authors H. Roché
  • Medicine
  • Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • 2007
Gemcitabine and platinum combinations in patients with breast cancer previously treated with anthracyclines and/or taxanes.
  • E. Perez
  • Medicine
  • Clinical breast cancer
  • 2004
Taxane-based reversal agents modulate drug resistance mediated by P-glycoprotein, multidrug resistance protein, and breast cancer resistance protein.
Targeting the microtubules in breast cancer beyond taxanes: the epothilones.
Improving the targeting of tubulin-binding agents: lessons from drug resistance studies.
Chemotherapy: what progress in the last 5 years?
  • A. Hamilton, G. Hortobagyi
  • Medicine
  • Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • 2005
...
1
2
3
4
5
...